Artificial intelligence (AI) software developer Viz.ai is partnering with Johns Hopkins University to facilitate patient enrollment in a clinical trial assessing a new treatment for intracerebral hemorrhage (ICH).
The company's Recruit software will be utilized by the university's BIOS Clinical Trials Coordinating Center to expedite patient enrollment in the Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) study, which is studying the safety and tolerability of a small molecule, MW189, for treating ICH. MW189 was developed by co-principal investigator Dr. Linda Van Eldik of the University of Kentucky.
Recruit scans patient images in real-time to identify patients at trial-eligible hospitals, enabling automatic identification of potential study subjects. Notifications are then sent to research teams, the company said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
